I see no issue with Recce competing the burns trial (at no expense to them) which will give us first clinical data in humans on a larger scale than previously obtained. IV trial is a double blinded placebo trial. Data is key. FDA can ask for more and it will be provided if needed.
Ann: Update on Phase I/II Clinical Trial for Burn Wound Infection, page-84
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 37.0¢ | $10.23K | 27.28K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3019 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 9138 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| RCE (ASX) Chart |